Anticancer agent 258

• Description:

  Anticancer agent 258 is an imidazo [1,2-B][1,2,4] triazol derivative. Anticancer agent 258 regulates the activity of nuclear receptors. Anticancer agent 258 has an EC50 of 63 nM against Nurr in N2A cells. Anticancer agent 258 has IC50 of 0.1 pM for Nur77 in HEK293 cells. Anticancer agent 258 can be used in the study of cancer, metabolic diseases and neurological disorders[1].

• UNSPSC:

  12352005

• Target:

  Nuclear Hormone Receptor 4A/NR4A; Orphan Receptor

• Related Pathways:

  GPCR/G Protein; Vitamin D Related/Nuclear Receptor

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cancer; Metabolic Disease; Neurological Disease

• Smiles:

  FC1=CC=C(C2=NN(C=C(N3C)C4=CC(F)=CC=C4)C3=N2)C=C1

• Molecular Formula:

  C17H12F2N4

• Molecular Weight:

  310.30

• References & Citations:

  [1]Antonio ALMARIO, et al. Imidazo[1,2-b][1,2,4]triazol derivatives for use in therapy. US20240300956A1. 2024-09-12.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2891984-12-4]